Enhanced Solubility and Functionality of Valrubicin (AD-32) Against Cancer Cells Upon Encapsulation into Biocompatible Nanoparticles

Overview

Journal Int J Nanomedicine

Publisher Dove Medical Press

Specialty Biotechnology

Date 2012 Mar 7

PMID 22393294

Citations 32

Authors

Nirupama Sabnis

Maya Nair

Mervyn Israel

Walter J McConathy

Andras G Lacko

Affiliations

Soon will be listed here.

Abstract

Among numerous drug-delivery approaches, reconstituted high-density lipoprotein (rHDL) nanocarriers have proven particularly applicable for delivering highly hydrophobic drugs. In this study, we have investigated the enhancement of the therapeutic impact of valrubicin (AD-32), an antineoplastic agent that has been limited to intravesicular application against bladder cancer, despite the encouraging original preclinical data. Earlier studies validated the superior therapeutic efficacy of AD-32 over doxorubicin. In the present study, rHDL/AD-32 nanoparticles were formulated and characterized with regard to encapsulation efficiency, physicochemical properties, selective toxicity, and receptor-mediated uptake. The half maximal inhibitory concentration values (IC(50)) for rHDL/AD-32 nanoparticles were 1.8 and 2.6 times lower than the free AD-32 for prostate (PC-3) and ovarian (SKOV-3) cancer cell lines, respectively, whereas nonmalignant cell lines demonstrated 5 and 1.48 times higher IC(50) doses with rHDL/AD-32 formulations. The data obtained demonstrated effective receptor- mediated uptake of AD-32 from the rHDL nanocarriers by PC-3 and SKOV-3 cancer cells via a targeted drug-delivery process. The rHDL/AD-32 formulation was stable for 6 months when stored at 4°C or at -20°C, as 92% of the AD-32 was retained in the nanoparticles. The findings from this study show that the rHDL/AD-32 formulation can overcome the solubility barriers of AD-32 and thus serve as an effective systemically administered chemotherapeutic agent.

Citing Articles

Reconstituted HDL ameliorated renal injury of diabetic kidney disease in mice.

Tao Y, Lacko A, Sabnis N, Das-Earl P, Ibrahim D, Crowe N Physiol Rep. 2024; 12(15):e16179.

PMID: 39107084 PMC: 11303015. DOI: 10.14814/phy2.16179.

High-Density Lipoprotein Subclasses and Their Role in the Prevention and Treatment of Cardiovascular Disease: A Narrative Review.

Chen Q, Abudukeremu A, Li K, Zheng M, Li H, Huang T Int J Mol Sci. 2024; 25(14).

PMID: 39063097 PMC: 11277419. DOI: 10.3390/ijms25147856.

Mannose-Coated Reconstituted Lipoprotein Nanoparticles for the Targeting of Tumor-Associated Macrophages: Optimization, Characterization, and In Vitro Evaluation of Effectiveness.

Dossou A, Mantsch M, Kapic A, Burnett W, Sabnis N, Coffer J Pharmaceutics. 2023; 15(6).

PMID: 37376134 PMC: 10304188. DOI: 10.3390/pharmaceutics15061685.

(Nano)platforms in bladder cancer therapy: Challenges and opportunities.

Ashrafizadeh M, Zarrabi A, Karimi-Maleh H, Taheriazam A, Mirzaei S, Hashemi M Bioeng Transl Med. 2023; 8(1):e10353.

PMID: 36684065 PMC: 9842064. DOI: 10.1002/btm2.10353.

Engineered rHDL Nanoparticles as a Suitable Platform for Theranostic Applications.

Aranda-Lara L, Isaac-Olive K, Ocampo-Garcia B, Ferro-Flores G, Gonzalez-Romero C, Mercado-Lopez A Molecules. 2022; 27(20).

PMID: 36296638 PMC: 9610567. DOI: 10.3390/molecules27207046.

References

McConathy W, Paranjape S, Mooberry L, Buttreddy S, Nair M, Lacko A . Validation of the reconstituted high-density lipoprotein (rHDL) drug delivery platform using dilauryl fluorescein (DLF). Drug Deliv Transl Res. 2015; 1(2):113-20. DOI: 10.1007/s13346-010-0012-0. View

Vecchi A, Cairo M, Mantovani A, Sironi M, Spreafico F . Comparative antineoplastic activity of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Treat Rep. 1978; 62(1):111-7. View

Guo D, Xu C, Quan J, Song C, Jin H, Kim D . Synergistic anti-tumor activity of paclitaxel-incorporated conjugated linoleic acid-coupled poloxamer thermosensitive hydrogel in vitro and in vivo. Biomaterials. 2009; 30(27):4777-85. DOI: 10.1016/j.biomaterials.2009.05.051. View

Hu L, Tang X, Cui F . Solid lipid nanoparticles (SLNs) to improve oral bioavailability of poorly soluble drugs. J Pharm Pharmacol. 2004; 56(12):1527-35. DOI: 10.1211/0022357044959. View

Israel M, Wilkinson P, Pegg W, Frei 3rd E . Hepatobiliary metabolism and excretion of adriamycin and N-trifluoroacetyladriamycin-14-valerate in the rat. Cancer Res. 1978; 38(2):365-70. View

Ibsen S, Zahavy E, Wrasdilo W, Berns M, Chan M, Esener S . A novel Doxorubicin prodrug with controllable photolysis activation for cancer chemotherapy. Pharm Res. 2010; 27(9):1848-60. PMC: 2916115. DOI: 10.1007/s11095-010-0183-x. View

Lacko A, Nair M, Prokai L, McConathy W . Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv. 2007; 4(6):665-75. DOI: 10.1517/17425247.4.6.665. View

Yang C, Zhao X, Hu H, Li K, Sun X, Li L . Preparation, optimization and characteristic of huperzine a loaded nanostructured lipid carriers. Chem Pharm Bull (Tokyo). 2010; 58(5):656-61. DOI: 10.1248/cpb.58.656. View

Ryan R, Forte T, Oda M . Optimized bacterial expression of human apolipoprotein A-I. Protein Expr Purif. 2003; 27(1):98-103. DOI: 10.1016/s1046-5928(02)00568-5. View

10.

Witjes J . Current recommendations for the management of bladder cancer. Drug therapy. Drugs. 1997; 53(3):404-14. DOI: 10.2165/00003495-199753030-00005. View

11.

Loney W, Kudchodkar B, Weis S, Clearfield M, Shores J, Lacko A . Evaluation of gemfibrozil therapy: predictive response from lipoprotein subfraction analysis. Am J Ther. 1999; 4(9-10):301-9. DOI: 10.1097/00045391-199709000-00004. View

12.

Jain K . Applications of nanobiotechnology in clinical diagnostics. Clin Chem. 2007; 53(11):2002-9. DOI: 10.1373/clinchem.2007.090795. View

13.

Yang S, Lu L, Cai Y, Zhu J, Liang B, Yang C . Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999; 59(3):299-307. DOI: 10.1016/s0168-3659(99)00007-3. View

14.

Leo E, CAMERONI R, Forni F . Dynamic dialysis for the drug release evaluation from doxorubicin-gelatin nanoparticle conjugates. Int J Pharm. 1999; 180(1):23-30. DOI: 10.1016/s0378-5173(98)00401-3. View

15.

Mooberry L, Nair M, Paranjape S, McConathy W, Lacko A . Receptor mediated uptake of paclitaxel from a synthetic high density lipoprotein nanocarrier. J Drug Target. 2009; 18(1):53-8. DOI: 10.3109/10611860903156419. View

16.

Israel M, MODEST E, Frei 3rd E . N-trifluoroacetyladriamycin-14-valerate, an analog with greater experimental antitumor activity and less toxicity than adriamycin. Cancer Res. 1975; 35(5):1365-8. View

17.

Krishan A, Israel M, MODEST E, Frei 3rd E . Differences in cellular uptake and cytofluorescence of adriamycin and N-trifluoroacetyladriamycin-14-valerate. Cancer Res. 1976; 36(6):2108-9. View

18.

Geze A, Venier-Julienne M, Mathieu D, Filmon R, Phan-Tan-Luu R, Benoit J . Development of 5-iodo-2'-deoxyuridine milling process to reduce initial burst release from PLGA microparticles. Int J Pharm. 1999; 178(2):257-68. DOI: 10.1016/s0378-5173(98)00380-9. View

19.

Lacko A, Nair M, Paranjape S, Johnso S, McConathy W . High density lipoprotein complexes as delivery vehicles for anticancer drugs. Anticancer Res. 2002; 22(4):2045-9. View

20.

Zheng J, Lee H, Bin Sattar M, Huang Y, Bian J . Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cardiomyocyte injury. Eur J Pharmacol. 2010; 652(1-3):82-8. DOI: 10.1016/j.ejphar.2010.10.082. View